1. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
- Author
-
Levy I, Lavi A, Zimran E, Grisariu S, Aumann S, Itchaki G, Berger T, Raanani P, Harel R, Aviv A, Lavi N, Zuckerman T, Shvidel L, Jarchowsky O, Ellis M, Herzog Tzarfati K, Koren-Michowitz M, Sherf Y, Levi I, Sofer O, Shpilberg O, Dally N, Suriu C, Braester A, Ben Barouch S, Leiba M, Goldstein D, Sarid N, Yeganeh S, Halloun J, Mittelman M, and Tadmor T
- Subjects
- Aged, Humans, Immunization, Passive, Retrospective Studies, SARS-CoV-2, COVID-19 Serotherapy, COVID-19 therapy, Hematologic Neoplasms complications, Hematologic Neoplasms epidemiology, Hematologic Neoplasms therapy
- Abstract
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease ( p = 0.036) and mortality ( p = 0.023), hypertension with severe/critical disease ( p = 0.046) and hospitalization ( p = 0.001), active haemato-oncological treatment with hospitalization ( p = 0.009), and remdesivir treatment was associated with decreased mortality ( p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.
- Published
- 2021
- Full Text
- View/download PDF